p63
Home Up Anti P Acetylated & phosphorylated p63 P73 alpha and beta PACAP Pancreatic Polypeptide Paracellin-1 Parkin & Synuclein Parvalbumin/Oncomodulin PAS3/JAP3 PTX3 and NPX1-2 PHM Per1, Per2 &  Per 3 PHEX/PEX Pit-1/GLVR1 & Pit-2 PGHS-1 and 2 Podocin & Podocalyxin Potassium Chloride Cotrans. Pre-pro Orexin Pref-1,FA1, DLK1,ZOG Presenilin-1 Proline Transporter Prostaglandin-endoperox Prostaglandin E Receptor PGT PUMA/JFY1

 

 

 

p73 - A Structural and Functional Homolog of p53- Antibodies

 

p53, the most frequent target of genetic alterations in human cancer, is one of the most widely studied tumor suppressor gene. The most important activities of p53 are its cellular growth arrest and induction of programmed cell death (apoptosis). Human p53 is a single polypeptide chain of 393 AA. It has three well-defined functional domains: An N-terminal acidic transactivation domain (TAD), a central DNA-binding domain (DBD), and a C-terminal homo-oligomerization domain (OD). All three domains are important for interaction with target genes. A great majority of tumor-associated missense mutations occur within the DBD and the mutant protein fails to regulate p53 target genes. Posttranslational modifications of p53 (phosphorylation and acetylation) have been implicated in its physiological role. p53 has at least 4 phosphorylation sites at the N-terminus with Ser15 as an important site in response to DNA damage and a target of the ATM and DNA PK proteins. There are three potential sites within the C-terminus of p53 that may affect its DNA-binding ability. p53 also serve as a substrate for various histone acetylases to enhance it transcriptional activity.

p63 has been identified as structural and functional homolog of p53. The p63 gene encodes several isoforms: p63alpha (also designated p51B or KET), p63beta and p63gamma (p51A), as well as corresponding TA* p63 isoforms, containing p53 transactivation domains. LNp63 isoforms lack the transactivation domain and inhibits transactivation by p53 and p63.

p73 appears to shares many structural and functional features of p53. Human p73 gene encodes two distinct polypeptides: The p73 long form (636 AA, termed p73alpha) and the short form (499 AA; termed p73beta). The short form arises through alternative splicing of the p73. With the exception of C-terminal 5 AA, p73beta is identical to p73alpha. Both p73a and p73b transcripts were detected all human tissues. The endogenous p73a protein has also been detected in cell extracts of HT-29, IMR-32, and SK-N-SH cells. The DBD domains of p53 and p73 show a 63% homology with a remarkable conservation of critical residues that are known to be important for the binding of p53 to target genes or proper folding of p53. A significant homology also exists in the TAD and OD of p53 and p73. The C-terminal domain (364-393) of p53 and p73 are quite distinct. p73 has been mapped to human chromosome 1p36, a region that is frequently deleted in variety of human cancers including neuroblastoma, colon cancer, and breast cancer.

 

 Items Antigen peptide location   Antibody Host  Expected Ab Crossreactivity  Neat Antisera Cat #
(100 ul)
Aff. Pure Ab
Cat #
(100 ug)
 * Control Peptide Cat#
(100 ug)
p73a and b
(Ab# 1)
H, 20 aa, NT Rb H (M, R?) P73A11-S P73A11-A  P73A11-P
p73a
(Ab# 2)
H, 22 aa ,CT Rb H (M, R?) P73A12-S P73A12-A P73A12-P
p73b
(Ab# 3)
h, 8 aa, CT Rb H (M, R?) P73B13-S P73B13-A P73B13-P
 p73b
(Ab# 5)
H, 120 aa, ~CT  M, mono  H, M, B   P73B15-M  
 p53 (w/m) h p53, ~15 aa NT  M, mono   P5311-M  
p53 (m) h p53, ~I M, Mono H, M, R, B - P5312-M -
 p53, S392
phosphospecific
Ser392, phosphopeptide   M, Mono H, M, R   P53S392-M  
 p53, Ac-K320
Acetylated
 K320 acetyalted peptide Rb   H - P53A320-S P53A320-P
 p53, Ac-K373
Acetylated
K373 acetyalted peptide   Rb  H    P53A3730-S P53A373-P
p63 (a, b, g) H, NT  M, Mono  H, M, R   P6311-M  
 Control Rabbit IgG  For use in ELISA, Western, Immunohisto. 20009-1 (1 mg)  

M= Mouse; R=Rat; H=Human; Rb=Rabbit; B=Bovine; CT= near C-terminus; NT=near N-terminus; I=Middle of protein; CL=Cytoplasmic loop; EC=Extracellular domain; IC=Intracellular domain; * w=wilde type; m=mutant p53

"Neat Antisera" are the unpurified antiserum and it is suitable for ELISA and Western.
"Affinity pure" antibodies have been over the antigen-affinity column and recommended for immunohistochemical applications.
"Control peptides" can not be used for Western as they are very short peptides. They are intended for ELISA or antibody competition studies.

All Products are for in vitro research use only.